La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Abnormal metabolic network activity in REM sleep behavior disorder

Identifieur interne : 000616 ( Pmc/Curation ); précédent : 000615; suivant : 000617

Abnormal metabolic network activity in REM sleep behavior disorder

Auteurs : Florian Holtbernd ; Jean-François Gagnon ; Ron B. Postuma ; Yilong Ma ; Chris C. Tang ; Andrew Feigin ; Vijay Dhawan ; Mélanie Vendette ; Jean-Paul Soucy ; David Eidelberg ; Jacques Montplaisir

Source :

RBID : PMC:3963420

Abstract

Objective:

To determine whether the Parkinson disease–related covariance pattern (PDRP) expression is abnormally increased in idiopathic REM sleep behavior disorder (RBD) and whether increased baseline activity is associated with greater individual risk of subsequent phenoconversion.

Methods:

For this cohort study, we recruited 2 groups of RBD and control subjects. Cohort 1 comprised 10 subjects with RBD (63.5 ± 9.4 years old) and 10 healthy volunteers (62.7 ± 8.6 years old) who underwent resting-state metabolic brain imaging with 18F-fluorodeoxyglucose PET. Cohort 2 comprised 17 subjects with RBD (68.9 ± 4.8 years old) and 17 healthy volunteers (66.6 ± 6.0 years old) who underwent resting brain perfusion imaging with ethylcysteinate dimer SPECT. The latter group was followed clinically for 4.6 ± 2.5 years by investigators blinded to the imaging results. PDRP expression was measured in both RBD groups and compared with corresponding control values.

Results:

PDRP expression was elevated in both groups of subjects with RBD (cohort 1: p < 0.04; cohort 2: p < 0.005). Of the 17 subjects with long-term follow-up, 8 were diagnosed with Parkinson disease or dementia with Lewy bodies; the others did not phenoconvert. For individual subjects with RBD, final phenoconversion status was predicted using a logistical regression model based on PDRP expression and subject age at the time of imaging (r2 = 0.64, p < 0.0001).

Conclusions:

Latent network abnormalities in subjects with idiopathic RBD are associated with a greater likelihood of subsequent phenoconversion to a progressive neurodegenerative syndrome.


Url:
DOI: 10.1212/WNL.0000000000000130
PubMed: 24453082
PubMed Central: 3963420

Links toward previous steps (curation, corpus...)


Links to Exploration step

PMC:3963420

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Abnormal metabolic network activity in REM sleep behavior disorder</title>
<author>
<name sortKey="Holtbernd, Florian" sort="Holtbernd, Florian" uniqKey="Holtbernd F" first="Florian" last="Holtbernd">Florian Holtbernd</name>
</author>
<author>
<name sortKey="Gagnon, Jean Francois" sort="Gagnon, Jean Francois" uniqKey="Gagnon J" first="Jean-François" last="Gagnon">Jean-François Gagnon</name>
</author>
<author>
<name sortKey="Postuma, Ron B" sort="Postuma, Ron B" uniqKey="Postuma R" first="Ron B." last="Postuma">Ron B. Postuma</name>
</author>
<author>
<name sortKey="Ma, Yilong" sort="Ma, Yilong" uniqKey="Ma Y" first="Yilong" last="Ma">Yilong Ma</name>
</author>
<author>
<name sortKey="Tang, Chris C" sort="Tang, Chris C" uniqKey="Tang C" first="Chris C." last="Tang">Chris C. Tang</name>
</author>
<author>
<name sortKey="Feigin, Andrew" sort="Feigin, Andrew" uniqKey="Feigin A" first="Andrew" last="Feigin">Andrew Feigin</name>
</author>
<author>
<name sortKey="Dhawan, Vijay" sort="Dhawan, Vijay" uniqKey="Dhawan V" first="Vijay" last="Dhawan">Vijay Dhawan</name>
</author>
<author>
<name sortKey="Vendette, Melanie" sort="Vendette, Melanie" uniqKey="Vendette M" first="Mélanie" last="Vendette">Mélanie Vendette</name>
</author>
<author>
<name sortKey="Soucy, Jean Paul" sort="Soucy, Jean Paul" uniqKey="Soucy J" first="Jean-Paul" last="Soucy">Jean-Paul Soucy</name>
</author>
<author>
<name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name>
</author>
<author>
<name sortKey="Montplaisir, Jacques" sort="Montplaisir, Jacques" uniqKey="Montplaisir J" first="Jacques" last="Montplaisir">Jacques Montplaisir</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">24453082</idno>
<idno type="pmc">3963420</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963420</idno>
<idno type="RBID">PMC:3963420</idno>
<idno type="doi">10.1212/WNL.0000000000000130</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">000616</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000616</idno>
<idno type="wicri:Area/Pmc/Curation">000616</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000616</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Abnormal metabolic network activity in REM sleep behavior disorder</title>
<author>
<name sortKey="Holtbernd, Florian" sort="Holtbernd, Florian" uniqKey="Holtbernd F" first="Florian" last="Holtbernd">Florian Holtbernd</name>
</author>
<author>
<name sortKey="Gagnon, Jean Francois" sort="Gagnon, Jean Francois" uniqKey="Gagnon J" first="Jean-François" last="Gagnon">Jean-François Gagnon</name>
</author>
<author>
<name sortKey="Postuma, Ron B" sort="Postuma, Ron B" uniqKey="Postuma R" first="Ron B." last="Postuma">Ron B. Postuma</name>
</author>
<author>
<name sortKey="Ma, Yilong" sort="Ma, Yilong" uniqKey="Ma Y" first="Yilong" last="Ma">Yilong Ma</name>
</author>
<author>
<name sortKey="Tang, Chris C" sort="Tang, Chris C" uniqKey="Tang C" first="Chris C." last="Tang">Chris C. Tang</name>
</author>
<author>
<name sortKey="Feigin, Andrew" sort="Feigin, Andrew" uniqKey="Feigin A" first="Andrew" last="Feigin">Andrew Feigin</name>
</author>
<author>
<name sortKey="Dhawan, Vijay" sort="Dhawan, Vijay" uniqKey="Dhawan V" first="Vijay" last="Dhawan">Vijay Dhawan</name>
</author>
<author>
<name sortKey="Vendette, Melanie" sort="Vendette, Melanie" uniqKey="Vendette M" first="Mélanie" last="Vendette">Mélanie Vendette</name>
</author>
<author>
<name sortKey="Soucy, Jean Paul" sort="Soucy, Jean Paul" uniqKey="Soucy J" first="Jean-Paul" last="Soucy">Jean-Paul Soucy</name>
</author>
<author>
<name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name>
</author>
<author>
<name sortKey="Montplaisir, Jacques" sort="Montplaisir, Jacques" uniqKey="Montplaisir J" first="Jacques" last="Montplaisir">Jacques Montplaisir</name>
</author>
</analytic>
<series>
<title level="j">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<idno type="eISSN">1526-632X</idno>
<imprint>
<date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<sec>
<title>Objective:</title>
<p>To determine whether the Parkinson disease–related covariance pattern (PDRP) expression is abnormally increased in idiopathic REM sleep behavior disorder (RBD) and whether increased baseline activity is associated with greater individual risk of subsequent phenoconversion.</p>
</sec>
<sec>
<title>Methods:</title>
<p>For this cohort study, we recruited 2 groups of RBD and control subjects. Cohort 1 comprised 10 subjects with RBD (63.5 ± 9.4 years old) and 10 healthy volunteers (62.7 ± 8.6 years old) who underwent resting-state metabolic brain imaging with
<sup>18</sup>
F-fluorodeoxyglucose PET. Cohort 2 comprised 17 subjects with RBD (68.9 ± 4.8 years old) and 17 healthy volunteers (66.6 ± 6.0 years old) who underwent resting brain perfusion imaging with ethylcysteinate dimer SPECT. The latter group was followed clinically for 4.6 ± 2.5 years by investigators blinded to the imaging results. PDRP expression was measured in both RBD groups and compared with corresponding control values.</p>
</sec>
<sec>
<title>Results:</title>
<p>PDRP expression was elevated in both groups of subjects with RBD (cohort 1:
<italic>p</italic>
< 0.04; cohort 2:
<italic>p</italic>
< 0.005). Of the 17 subjects with long-term follow-up, 8 were diagnosed with Parkinson disease or dementia with Lewy bodies; the others did not phenoconvert. For individual subjects with RBD, final phenoconversion status was predicted using a logistical regression model based on PDRP expression and subject age at the time of imaging (
<italic>r</italic>
<sup>2</sup>
= 0.64,
<italic>p</italic>
< 0.0001).</p>
</sec>
<sec>
<title>Conclusions:</title>
<p>Latent network abnormalities in subjects with idiopathic RBD are associated with a greater likelihood of subsequent phenoconversion to a progressive neurodegenerative syndrome.</p>
</sec>
</div>
</front>
</TEI>
<pmc article-type="research-article">
<pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurology</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurology</journal-id>
<journal-id journal-id-type="hwp">neurology</journal-id>
<journal-id journal-id-type="publisher-id">neur</journal-id>
<journal-id journal-id-type="pmc">neurology</journal-id>
<journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id>
<journal-title-group>
<journal-title>Neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0028-3878</issn>
<issn pub-type="epub">1526-632X</issn>
<publisher>
<publisher-name>Lippincott Williams & Wilkins</publisher-name>
<publisher-loc>Hagerstown, MD</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">24453082</article-id>
<article-id pub-id-type="pmc">3963420</article-id>
<article-id pub-id-type="publisher-id">NEUROLOGY2013544395</article-id>
<article-id pub-id-type="doi">10.1212/WNL.0000000000000130</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>165</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Abnormal metabolic network activity in REM sleep behavior disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Holtbernd</surname>
<given-names>Florian</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="author-notes" rid="fn1">*</xref>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment & Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gagnon</surname>
<given-names>Jean-François</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="author-notes" rid="fn1">*</xref>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1) Canadian Institutes of Health Research [(MOP-84482, PI, 2007-2012), (MOP-62955, Co-PI, 2008-2013), (MOP-93802, Co-PI, 2010-2015), (MOP-191058, Co-In, 2009-2014), (MOP-123294, Co-In, 2012-2017), and New investigator salary award, 2012-2017)]. (2) Fonds de Recherche du Qu�bec � Sant� [(R�seau Parkinson Qu�bec, Co-In, 2012-2016), and (Chercheur boursier junior award, 2012-2016)].</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment & Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Postuma</surname>
<given-names>Ron B.</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>(1) Teva Neurosciences, Panel Member, 2008</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>(1) Allergan, 2011; (2) Teva Neurosciences, 2011 & 2013, Novartis 2012</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>(1) Editorial Board, Movement Disorders Journal; (2) Editorial Board, Journal of Caffeine Research</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1) Operating Grant - Canadian Institute of Health Research/Parkinson Society of Canada, grant number 201317, Principal Investigator (10/2009 � 10/2011); (2) Operating Grant � Canadian Institute of Health Research, grant number 192205, co-Principal Investigator (07/2009 � 06/2010); (3) Operating Grant - Canadian Institute of Health Research, grant number 166206 Co-investigator (07/2007 to 06/2012); (4) An Emerging Team in Mobility in Aging Operating Grant - Canadian Institute of Health Research, Co-investigator (01/2009 � 12/1013); (4) Fonds de Recherche de la Sante Quebec, grant number 9965, Principal Investigator (2006-2009) (5) Canadian Insititute of Health Researech, grant number N/A, July 2013 - 2019</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>(3) Operating Grant - Webster foundation, Grant number N/A, 01/2013-12/2020 (2) Operating Grant � Weston Foundation, Prinicipal Investigator (01/2009 � 01/2011); (1) Operating grant - Drummond Foundation, Principal Investigator (01/2008 - 04/2009)</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment & Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Yilong</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>Neurologix,PI:A. Feigin,08/01/08 � 07/31/10, Imaging Engineer</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NIH/Morris K. Udall Center of Excellence for Parkinson�s Disease P50 NS071675,PI: D. Eidelberg 09/30/10�08/31/15, Core Leader (Imaging Core � PET) NIH U01 NS 083173, PI: A. Feigin 04/01/13-03/31/16, Co-Investigator NIH R01 NS 083490, PI: Y. Ma 9/15/2013 � 7/31/2016</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Michael J. Fox Foundation, PI: D. Eidelberg 11/01/12 � 10/31/15, Co-Investigator</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment & Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tang</surname>
<given-names>Chris C.</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment & Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Feigin</surname>
<given-names>Andrew</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>1) Teva, scientific advisory board 2) Lundbeck. scientific advisory board 3) Prana, DSMB chair 4) Auspex, DSMB member</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>1) Allergan, paid speaker 2) Teva, paid speaker</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>1) Neurology Today, editorial board, 2011-present 2) Journal of Huntington's, editorial board, 2012-present</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>Third Rock Ventures Omeros Pharmaceuticals</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>1) Allergan, Inc. 2) TEVA Pharmaceutical Industries Ltd</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1) NIH/NINDS, U10 NS044484, Principal Investigator, 09/30/02 � 11/30/12, (2)NIH/NCRR, M01 RR018535, 04/22/08 � 03/31/11, Associate Program Director, (3) NIH/NINDS, U01 NS083173, Principal Investigator</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>(1) Huntington�s Disease Society of America</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment & Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dhawan</surname>
<given-names>Vijay</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>Neurologix,PI:A. Feigin,08/01/08 � 07/31/10,Biophysicist</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>1. NIH/NIDCD,R01 DC007658,PI:J. Sidtis,04/01/06� 03/31/11,Co-Investigator 2. NIH/NIAID,P01 AI073693,PI:B. Diamond,08/01/08� 07/31/13,Co-Investigator</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Dana Foundation,PI:A. Feigin,07/01/08 � 06/30/10,Co-Investigator</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment & Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vendette</surname>
<given-names>Mélanie</given-names>
</name>
<degrees>MSc</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment & Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Soucy</surname>
<given-names>Jean-Paul</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Member, Editorial Board, Advances in Alzheimer�s Disease, 2012 -</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>I practice Nuclear Medicine at both the Montreal University Medical Centre and Montreal Neurological Hospital, and I report both SPECT rCBF studies and PET FDG brain studies as a practitioner.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>24. Beta-cell imaging with 18F-labeled glibenclamide-glucose conjugates by positron emission tomography. CIHR 97970; SCHIRRMACHER, R, SOUCY, JP; $79,462/ann�e x 3 ans (2010) 25. Sleep and mild cognitive impairment. CIHR MOP-102631. MONTPLAISIR J, GAGNON JF, GOSSELIN N, MONCHY O, SOUCY JP. $169,465/ann�e X 5 ans (2010) 26. Anatomobehavioral validation of the [18F]fluoroethoxybenzovesamicol, as a PET radiotracer for the diagnosis of Alzheimer�s disease. CIHR. Co-PI: B�DARD MA, SOUCY JP, ROSA P. Collaborators : DESCARRIES L, MESHAWAR N. $50 000.00 X 1 an (2010) 27. Development of an automated blood counter for quantitative molecular imaging applications. Despr�s, Philippe (IP). CO-APPLICANT(S): Soucy, Jean-Paul; Rosa Neto, Pedro; Hamel, Louis-Andr�. Projets de recherche concert�e sur la sant� (PRCS), programme conjoint CRSNG et IRSC. Projet # 1004158. 2010: $73000, 2011: $110300, 2012: $61800 28. In vivo quantification of glutamatergic abnormalities in patients with Alzheimer's disease. Rosa-Neto, Pedro (IP); Co-applicants: Gauthier, Serge; Soucy, Jean-Paul. IRSC, demande # 245908, comit� BCA. $196,180/ann�e X 4 ans (2011-2014) 29. The neuro-circuitry of terror: High resolution SPECT imaging of REM sleep in PTSD and Nightmare Disorder. IPs: Nielsen, Torre; Soucy, Jean-Paul. Co-applicant: Montplaisir, Jacques. CIHR MOP-115125. $135 550/ann�e X 5 ans (2011-2015) 30. Anomia in Alzheimer�s disease : Untangling semantic components and delivering therapy with rTMS. Chertkow Howard, Soucy Jean-Paul, Thiel Alexander. CIHR 259005. $153 303.00/year, 2012-2015 31. Obstructive sleep apnea and mild cognitive impairment. N Gosselin , J. Y. Montplaisir, L. De Beaumont, J. Gagnon, S. Gauthier, J. P. Soucy. CIHR 272199. $157,816/ann�e, 2012-2016</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment & Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Eidelberg</surname>
<given-names>David</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="author-notes" rid="fn2"></xref>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>(1) The Michael J. Fox Foundation for Parkinson's Research (2) The Bachmann-Strauss Dystonia and Parkinson Foundation (3) Thomas Hartman Foundation for Parkinson�s Research, Inc.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>(1) Journal of Nuclear Medicine, editorial board, 1999-present (2) Current Opinion in Neurology, editorial board, 2001-present (3) Annals of Neurology, editorial board, 2006-present (4) Journal of Neuroscience, Associate Editor, 2011-present (5) NeuroImage, editorial board, 2011-present</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>Coinventor of United States Patent NO. 5,632,276 (filed January 27, 1995, granted May 27, 1997) and NO. 5,873,823 (filed September 4, 1996, granted February 23, 1999), without financial gain.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>The Feinstein Institute for Medical Research, North Shore-LIJ Health System, not-for-profit</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>Pfizer</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1) NIH/NINDS, P50 NS071675, PI, 09/30/10�08/31/15 (2) NIH/NIAID, P01 AI073693, Co-PI, 08/01/08� 07/31/13 (3) NIH/NINDS, R01 NS072514, PI, 04/01/11 � 3/31/15</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>(1) The Dana Foundation (2) The Bachmann-Strauss Dystonia and Parkinson Foundation (3) High Q Foundation</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment & Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Montplaisir</surname>
<given-names>Jacques</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="author-notes" rid="fn2"></xref>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>Advisory Board: Servier, Merck, Sanofi-Aventis, Valeant Pharmaceutical,GSK Pharma, Jazz Pharmaceutical, Impax Laboratory, V-Watch,</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>Valeant Pharmaceutical, Speaker 2010 and 2011; Otsuka Pharmaceutical, Speaker, Japan 2011</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>(1) Associate editor: Sleep Medicine 2000 - 2011</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>Merck 2010-2011 - Unrelated to the study GlaxoSmithKline 2011-2013 - Unrelated to the study</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>PI: CIHR - MOP-62955 - 2008-2013; PI: CIHR - MOP-106692 - 2011-2015 PI: CIHR- MOP- 102631 - 2010-2015 Co-I: CIHR - MOP- 97825 � 2011-2016; Co-I: CIHR - MOP-115125 � 2012-2017; Co-PI: CIHR - MOP 173519 � 2007-2012 Co-I: CIHR - MOP 64221 - 2008-2012</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment & Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<aff>From the Center for Neurosciences (F.H., Y.M., C.C.T., A.F., V.D., D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; Center for Advanced Research in Sleep Medicine (J.-F.G., R.B.P., M.V., J.M.), Hôpital du Sacré-Coeur de Montréal; Department of Psychology (J.-F.G., M.V.), Université du Québec à Montréal; Department of Neurology (R.B.P.), Montreal General Hospital; Montreal Neurological Institute (J.-P.S.), McGill University; and Department of Psychiatry (J.M.), University of Montreal, Montréal, Canada.</aff>
</contrib-group>
<author-notes>
<corresp>Correspondence to Dr. Eidelberg:
<email>david1@nshs.edu</email>
</corresp>
<fn fn-type="other" id="fn1">
<label>*</label>
<p>These authors contributed equally to this work.</p>
</fn>
<fn fn-type="other" id="fn2">
<label></label>
<p>These authors share senior authorship.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>Go to
<ext-link ext-link-type="uri" xlink:href="http://neurology.org/">Neurology.org</ext-link>
for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>18</day>
<month>2</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>18</day>
<month>8</month>
<year>2014</year>
</pub-date>
<pmc-comment> PMC Release delay is 6 months and 0 days and was based on the . </pmc-comment>
<volume>82</volume>
<issue>7</issue>
<fpage>620</fpage>
<lpage>627</lpage>
<history>
<date date-type="received">
<day>15</day>
<month>8</month>
<year>2013</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>11</month>
<year>2013</year>
</date>
</history>
<permissions>
<copyright-statement>© 2014 American Academy of Neurology</copyright-statement>
<copyright-year>2014</copyright-year>
<copyright-holder>American Academy of Neurology</copyright-holder>
</permissions>
<self-uri xlink:title="pdf" xlink:type="simple" xlink:href="NEUROLOGY2013544395.pdf"></self-uri>
<abstract>
<sec>
<title>Objective:</title>
<p>To determine whether the Parkinson disease–related covariance pattern (PDRP) expression is abnormally increased in idiopathic REM sleep behavior disorder (RBD) and whether increased baseline activity is associated with greater individual risk of subsequent phenoconversion.</p>
</sec>
<sec>
<title>Methods:</title>
<p>For this cohort study, we recruited 2 groups of RBD and control subjects. Cohort 1 comprised 10 subjects with RBD (63.5 ± 9.4 years old) and 10 healthy volunteers (62.7 ± 8.6 years old) who underwent resting-state metabolic brain imaging with
<sup>18</sup>
F-fluorodeoxyglucose PET. Cohort 2 comprised 17 subjects with RBD (68.9 ± 4.8 years old) and 17 healthy volunteers (66.6 ± 6.0 years old) who underwent resting brain perfusion imaging with ethylcysteinate dimer SPECT. The latter group was followed clinically for 4.6 ± 2.5 years by investigators blinded to the imaging results. PDRP expression was measured in both RBD groups and compared with corresponding control values.</p>
</sec>
<sec>
<title>Results:</title>
<p>PDRP expression was elevated in both groups of subjects with RBD (cohort 1:
<italic>p</italic>
< 0.04; cohort 2:
<italic>p</italic>
< 0.005). Of the 17 subjects with long-term follow-up, 8 were diagnosed with Parkinson disease or dementia with Lewy bodies; the others did not phenoconvert. For individual subjects with RBD, final phenoconversion status was predicted using a logistical regression model based on PDRP expression and subject age at the time of imaging (
<italic>r</italic>
<sup>2</sup>
= 0.64,
<italic>p</italic>
< 0.0001).</p>
</sec>
<sec>
<title>Conclusions:</title>
<p>Latent network abnormalities in subjects with idiopathic RBD are associated with a greater likelihood of subsequent phenoconversion to a progressive neurodegenerative syndrome.</p>
</sec>
</abstract>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000616 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000616 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Pmc
   |étape=   Curation
   |type=    RBID
   |clé=     PMC:3963420
   |texte=   Abnormal metabolic network activity in REM sleep behavior disorder
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i   -Sk "pubmed:24453082" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022